Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Pol, Tymon; Held, Claes; Westerbergh, Johan; Lindback, Johan; Alexander, John; Alings, Marco; EROL, ÇETİN; Goto, Shinya; Halvorsen, Sigrun; Huber, Kurt; Hanna, Michael; Lopes, Renato; Ruzyllo, Witold; Granger, Christopher; Hijazi, Ziad

doi:10.1161/jaha.117.007444

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial

Pol T., Held C., Westerbergh J., Lindback J., Alexander J. H., Alings M., ...Daha Fazla

JOURNAL OF THE AMERICAN HEART ASSOCIATION, cilt.7, sa.3, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7 Sayı: 3
Basım Tarihi: 2018
Doi Numarası: 10.1161/jaha.117.007444
Dergi Adı: JOURNAL OF THE AMERICAN HEART ASSOCIATION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Anahtar Kelimeler: atrial fibrillation, biomarkers, cardiovascular disease, cerebrovascular disease, stroke, DENSITY-LIPOPROTEIN CHOLESTEROL, INFLAMMATION, MORTALITY, ASSOCIATION, BIOMARKERS, DISEASE, ATHEROSCLEROSIS, STRATIFICATION, PREVENTION, WARFARIN
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Evet

Özet

BackgroundDyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (ApoB) and cardiovascular events in patients with atrial fibrillation receiving oral anticoagulation.